NLRP3 inflammasome–driven hemophagocytic lymphohistiocytosis occurs independent of IL-1β and IL-18 and is targetable by BET inhibitors
Science Advances · 2025
DOI: 10.1126/sciadv.adv0079 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, 2025. Verfasst von Farzaneh Shojaee und 14 weiteren Autor:innen. Beteiligte Einrichtung: The Walter and Eliza Hall Institute of Medical Research, Parkville 3052, Australia. Hauptthemen laut MEDLINE: NLR Family, Pyrin Domain-Containing 3 Protein, Interleukin-1beta, Inflammasomes, Interleukin-18. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 93 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Hemophagocytic lymphohistiocytosis (HLH) is a potentially fatal cytokine storm syndrome. Its high mortality rate reflects limited therapeutic options and a poor understanding of disease-causing signaling. We show that the NLRP3 inflammasome is responsible for increased mortality in a model of secondary HLH (sHLH). Unexpectedly, neither deletion of the NLRP3-activated pyroptotic effector GSDMD nor combined deletion of the inflammasome-activated cytokines interleukin-1β (IL-1β) and IL-18 conferred strong protection from sHLH. Instead, co-deletion of GSDMD and caspase-8–activated GSDME limited sHLH-driven lethality, demonstrating redundancy in the pyroptotic machinery required to induce sHLH. We also found that bromodomain and extraterminal domain (BET) inhibitors prevent NLRP3-driven pyroptosis, which acted by blocking inflammasome priming. BET inhibitors prevented increased NLRP3 levels in diseased tissue, limited the production of sHLH-associated IL-1β, interferon-γ, and tumor necrosis factor, and protected from sHLH pathogenesis. These findings suggest that targeting NLRP3 could limit sHLH and identify clinically relevant bromodomain-selective BET inhibitors capable of eliminating NLRP3-driven pyroptosis and the sHLH cytokine storm.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- The Walter and Eliza Hall Institute of Medical Research, Parkville 3052, Australia.
- Department of Medical Biology, University of Melbourne, Parkville 3010, Australia.
- Department of Biological Sciences, National University of Singapore, Singapore 117558, Singapore.
- Dorevitch Pathology, Heidelberg 3084, Australia.
- Olivia Newton-John Cancer and Wellness Centre, Austin Health, Heidelberg 3084, Australia.
- School of Cancer Medicine, La Trobe University, Heidelberg 3084, Australia.
ORCID-Profile: Farzaneh Shojaee, Min Xian Wong, Xiuquan Ma, Jiyi Pang, Andrew J Kueh, Seth L Masters, Inmaculada Rioja, Kate E Lawlor, Maryam Rashidi, James E Vince
Zitieren
APA
Shojaee, F., Azadian, E., Wong, M. X., Ma, X., Rickard, J., Pang, J., Hall, C., Kueh, A. J., Masters, S. L., Rioja, I., Prinjha, R. K., Doerflinger, M., Lawlor, K. E., Rashidi, M., & Vince, J. E. (2025). NLRP3 inflammasome–driven hemophagocytic lymphohistiocytosis occurs independent of IL-1β and IL-18 and is targetable by BET inhibitors. Science Advances. https://doi.org/10.1126/sciadv.adv0079
Vancouver
Shojaee F, Azadian E, Wong MX, Ma X, Rickard J, Pang J, et al. NLRP3 inflammasome–driven hemophagocytic lymphohistiocytosis occurs independent of IL-1β and IL-18 and is targetable by BET inhibitors. Science Advances. 2025. doi:10.1126/sciadv.adv0079
BibTeX
@article{Shojaee2025,
author = {Shojaee, Farzaneh and Azadian, Esmaeel and Wong, Min Xian and Ma, Xiuquan and Rickard, James and Pang, Jiyi and Hall, Catherine and Kueh, Andrew J and Masters, Seth L and Rioja, Inmaculada and Prinjha, Rab K and Doerflinger, Marcel and Lawlor, Kate E and Rashidi, Maryam and Vince, James E},
title = {NLRP3 inflammasome–driven hemophagocytic lymphohistiocytosis occurs independent of IL-1β and IL-18 and is targetable by BET inhibitors},
journal = {Science Advances},
year = {2025},
doi = {10.1126/sciadv.adv0079}
}
EUVIMED